MET and neoplasm: To determine if MET status influences tumor response to HER2 inhibition, we examined the colony formation and tumor growth of isogenic H2170 clones treated with the HER2 TKIs (lapatinib, ASLAN001) and monoclonal antibodies (trastuzumab and pertuzumab).